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Background: Prior studies suggest that obstructive sleep apnea may be associated with gastroesophageal reflux disease,
a strong risk factor for Barrett’s esophagus. The goals of this pilot case–control study were to determine whether Barrett’s
esophagus patients have an increased likelihood of obstructive sleep apnea and to determine whether nocturnal
gastroesophageal reflux symptoms affect the relationship between Barrett’s esophagus and obstructive sleep apnea risk.
Methods: Patients with Barrett’s esophagus completed the Berlin Questionnaire, a validated survey instrument identifying
subjects at high risk for obstructive sleep apnea. Two outpatient control groups were recruited: 1) EGD Group, subjects
matched to Barrett’s esophagus cases by age, race, and gender with esophagogastroduodenoscopy negative for Barrett’s
esophagus; and 2) Colonoscopy Group, patients getting colonoscopy. Rates of scoring at high risk for obstructive sleep
apnea were compared. Respondents were also questioned regarding severity of their typical gastroesophageal reflux
symptoms and presence of nocturnal gastroesophageal reflux symptoms.
Results: The study included 287 patients (54 Barrett’s esophagus, 62 EGD, and 171 colonoscopy subjects). Barrett’s
esophagus patients were slightly older than colonoscopy patients and more obese. 56% (n = 30) of Barrett’s esophagus
subjects scored at high risk for obstructive sleep apnea, compared with 42% (n = 26) of EGD subjects (OR 1.73, 95% CI
[0.83, 3.62]) and 37% (n = 64) of colonoscopy patients (OR 2.08, 95% CI [1.12, 3.88]). The association between Barrett’s
esophagus and scoring at high risk for obstructive sleep apnea compared with colonoscopy patients disappeared after
adjusting for age. Barrett’s esophagus patients reported more severe typical heartburn and regurgitation symptoms than
either control group. Among all subjects, patients with nocturnal reflux symptoms were more likely to score at high risk
for obstructive sleep apnea than patients without nocturnal reflux.
Conclusions: In this pilot study, a high proportion of Barrett’s esophagus subjects scored at high risk for obstructive
sleep apnea. Having Barrett’s esophagus was associated with more severe gastroesophageal reflux symptoms, and
nocturnal reflux symptoms were associated with scoring at high risk for obstructive sleep apnea. The need for
obstructive sleep apnea screening in Barrett’s esophagus patients with nocturnal gastroesophageal reflux symptoms
should be further evaluated.
Keywords: Barrett’s esophagus, Gastroesophageal reflux disease, Obesity, Obstructive sleep apneaBackground
Esophageal adenocarcinoma (EAC) has dramatically in-
creased in incidence in the United States over the last 3 de-
cades [1,2] and is strongly linked to its precursor
metaplastic lesion, Barrett’s esophagus (BE), and gastro-
esophageal reflux disease (GERD) [3]. Current guidelines
recommend considering endoscopic screening of patients* Correspondence: linda.cummings@case.edu
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distribution, and reproduction in any mediumwith multiple risk factors for Barrett’s esophagus including
chronic GERD symptoms [4]. Studies suggest that 8%-13%
of patients with GERD have BE [5,6], compared with a rate
of 1%-6% in patients without heartburn symptoms [6,7].
The risk of BE increases with increasing duration of reflux
symptoms, particularly nocturnal symptoms [3,8]. More-
over, GERD patients with BE typically have a greater dur-
ation of esophageal acid exposure than those without BE.
BE and esophageal adenocarcinoma are also associated
with obesity [9-11]. The increase in obesity in the United
States over the past several decades has been proposed astral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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carcinoma. Obesity and its associated health conditions rep-
resent a growing public health concern in the United
States. Obesity-associated obstructive sleep apnea (OSA),
for example, is an important albeit underdiagnosed syn-
drome with detrimental cardiovascular and neurocognitive
effects. Like those at risk for BE, patients at risk for OSA
are typically male, obese, and middle-aged.
Prior theory and evidence suggest that OSA is associated
with gastroesophageal reflux disease. It has been theorized
that negative intrapleural pressures generated during noc-
turnal airway obstruction in OSA could contribute to noc-
turnal gastroesophageal reflux [12,13], although studies
have not demonstrated a direct relationship between ob-
structive events and nocturnal GERD events [12,14]. Alter-
natively, it is possible that obstructive events could lead to
weakening at the lower esophageal sphincter over time [14].
A population-based study reported increased nocturnal
GERD symptoms in patients with sleep-disordered breath-
ing symptoms [15]. A large cohort study suggested that
nocturnal GERD may be associated with increased body
mass index and sleep complaints [16]. A study of 1093
OSA patients found that frequent nocturnal GERD was as-
sociated with more severe OSA, independent of body mass
index [13]. Other studies have demonstrated that treatment
of OSA with continuous positive airway pressure effectively
treats nocturnal gastroesophageal reflux symptoms [17,18].
Continuous positive airway pressure treatment in OSA pa-
tients with GERD significantly reduced nocturnal acid con-
tact time as measured by esophageal pH monitoring [18].
Metabolic changes associated with OSA including increased
oxidative stress [19] and alteration in serum levels of insulin
and insulin-like growth factors [20] could predispose to BE.
The role of nocturnal reflux in Barrett’s esophagus needs
further investigation. Although some studies have suggested
that nocturnal reflux symptoms are not associated with
Barrett’s esophagus among GERD patients [21,22], other
studies have measured increased nocturnal esophageal acid
exposure [23] or nocturnal non-acid reflux [24] in BE pa-
tients compared with GERD patients without BE.
Given the growing body of evidence associating OSA
with gastroesophageal reflux disease, this pilot study aimed
to determine whether patients with BE are more likely to
be at risk for OSA. We hypothesized that BE patients would
be more likely to score at high risk for OSA on a survey in-
strument for OSA screening compared with controls. We
also aimed to determine if nocturnal gastroesophageal re-
flux symptoms affected the relationship between BE and
high risk for OSA.
Methods
The study was approved by the University Hospitals Case
Medical Center Institutional Review Board and was
performed in accordance with the Declaration of Helsinki.We performed a pilot case–control study comparing risk
for OSA between subjects with Barrett’s esophagus and 2
control groups. Risk for OSA was determined based on an
addended version of the Berlin Questionnaire, a validated
survey instrument used for OSA screening that identifies
subjects at high risk for OSA [25,26]. Two control groups
identified from patients undergoing outpatient endoscopy
were recruited including patients from another study as
previously described [27]: 1) Subjects matched to BE cases
by age ± 5 years, race, and gender with upper endoscopy
negative for BE (hereafter referred to as the EGD group);
and 2) Patients presenting for outpatient colonoscopy, in-
cluding open-access cases, who had no prior upper endos-
copy at our facility (hereafter referred to as the COL
group). If possible, we matched up to 3 EGD control sub-
jects per BE case subject by age (at time of survey) ± 5
years, race, and gender. The survey was distributed via
mailings to BE patients who had previously undergone
upper endoscopy and in person at the time of endoscopy.
The vast majority of control subjects were recruited at the
time of endoscopy, with 2 EGD control subjects completing
their surveys < 14 days after an upper endoscopy negative
for BE. Informed consent was obtained from all subjects.
Inclusion/exclusion criteria
Barrett’s esophagus cases included patients with a known
diagnosis of histologically confirmed short-segment or
long-segment Barrett’s esophagus followed for surveillance
in our endoscopy lab as well as incident BE cases diag-
nosed at the time of survey completion based on endo-
scopic and histological findings. An existing Barrett’s
esophagus database was used to identify potential cases. In
addition, the results of a pathology database search for in-
testinal metaplasia were used in conjunction with endos-
copy reports to identify potential cases; for these purposes,
intestinal metaplasia had to be present on ≥1 biopsy of
salmon-colored mucosa from the distal esophagus. We ex-
cluded patients with a known diagnosis of obstructive
sleep apnea because it was felt that the results of the
Berlin Questionnaire might be difficult to interpret in
OSA patients compliant with therapy; additionally, the
control groups included a subset of patients from another
study [27] in which those with OSA were excluded up
front and therefore did not complete the Berlin Question-
naire. We excluded patients with esophageal adenocarcin-
oma, patients aged <18 years, those unable to give
consent, and those unable to read or respond to survey
questions. In addition, patients with malignancy with dis-
tant metastases or those with malignancy who had under-
gone radiation or chemotherapy within 1 year prior to the
survey were excluded. Electronic medical records were
reviewed for documentation of metastatic disease and ra-
diation or chemotherapy treatment. Surveys were admin-
istered between September 2006 and May 2008.
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The Berlin Questionnaire (BQ) is a brief survey that has
been validated as a means of identifying patients that are
at risk for OSA [25]. This questionnaire asks about
weight change, daytime sleepiness, snoring, and presence
or absence of hypertension. Based on their responses,
subjects are considered to be at high risk for OSA if they
meet requirements for at least 2 of 3 symptom categor-
ies: 1) persistent symptoms (>3 to 4 times/week) in 2 or
more questions about snoring; 2) persistent (>3 to 4
times/week) daytime somnolence and/or drowsiness while
driving; and 3) body mass index (BMI) of more than 30
kg/m2 (based on self-reported height and weight in this
study) or history of high blood pressure. In a primary care
setting, being identified by the Berlin Questionnaire to be
at high risk for OSA predicted a respiratory disturbance
index (RDI) greater than 5 with a sensitivity of 0.86, a spe-
cificity of 0.77, a positive predictive value of 0.89, and a
likelihood ratio of 3.79 [25]. The Berlin Questionnaire has
also been validated in surgical patients [28].
To better assess risk factors, the Berlin Questionnaire
was addended with standardized questions regarding the
severity of the subject’s typical GERD symptoms (see
subsection Summary of Modified Berlin Questionnaire)
and presence of nocturnal regurgitation and heartburn.
Heartburn or regurgitation symptoms were considered
present if the respondent rated his/her usual heartburn
or acid regurgitation symptoms as at least mild in sever-
ity. Severe heartburn or acid regurgitation symptoms
were defined as lifestyle-affecting. Nocturnal gastro-
esophageal reflux symptoms were considered present if
the respondent reported that heartburn or acid regurgi-
tation had awakened him/her in the past year. Nocturnal
regurgitation was imputed as absent for 1 COL patient
who did not answer the question regarding awakening
by nocturnal regurgitation in the past year, but rated his
usual acid regurgitation symptoms as nonexistent.
Summary of Modified Berlin Questionnaire
A summary of the modified Berlin Questionnaire used
in the study, including the Berlin Questionnaire and
its scoring system and additional questions regarding
gastroesophageal reflux disease symptoms, is presented
below.
Subjects were considered to be at high risk for ob-
structive sleep apnea if ≥2 of 3 symptom categories were
positive. Categories 1 and 2 were considered positive if
the patient answered yes to ≥2 questions, and Category
3 was considered positive if the patient answered yes
to ≥1 question.
Category 1: Snoring
 Does the patient snore?
 Does the patient snore ≥3-4 times per week? Does the patient stop breathing while sleeping ≥3-4
times per week?
 Is the patient’s snoring at least louder than talking?
 Does the snoring bother other people?
Category 2: Daytime Somnolence
 Does the patient feel tired after sleeping ≥3-4 times
per week?
 Does the patient feel tired during waketime ≥3-4
times per week?
 Has the patient ever fallen asleep while driving?
 Does falling asleep while driving occur ≥3-4 times
per week?
Category 3: Obesity/Hypertension
 Does the patient have high blood pressure?
 Does the patient have a body mass index >30?
(Based on self-reported height and weight)
Questions regarding Gastroesophageal Reflux Disease
Questions about heartburn
 Severity rating of the patient’s typical heartburn
(nonexistent, mild, moderate, or severe)
 Has heartburn awakened the patient at night in the
past year?
Questions about acid regurgitation
 Severity rating of the patient’s typical acid
regurgitation (nonexistent, mild, moderate, or
severe)
 Has acid regurgitation awakened the patient at night
in the past year?
Power calculation/Study population
We anticipated based on our population of appro-
ximately 150 BE patients that are regularly followed at
our Digestive Health Institute and an expected survey
response rate of 50% that we would be able to capture
75 BE cases. Prior studies in the United States using the
Berlin Questionnaire in primary care settings and a car-
diology referral clinic found that 32%-36% of subjects
were identified as being at high risk for OSA [26,29]. As-
suming a 35% prevalence of being at high risk for OSA
(hereafter referred to as BQ+) in the control group and
a 55% prevalence of being BQ+ in our case group, our
study would have 83% power to detect this difference at
α = 0.05. Of note, our study findings were consistent
with the incidences arrived at in our power calculation.
This calculation did not account for matching, which
should increase the power of the study.
We recruited 73 Barrett’s esophagus cases and 242 con-
trols, of which 66 were in the EGD group and 176 were in
the COL group. The final comparison groups were
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patients, and 171 COL control patients after the following
exclusions: 6 BE cases with esophageal adenocarcinoma;
4 subjects with recent chemotherapy or radiation for ma-
lignancy (1 BE case, 2 EGD patients, and 1 COL patient);
4 COL patients with metastatic disease; 11 BE cases previ-
ously diagnosed with OSA (n = 10) or missing OSA status
(n = 1); 2 EGD patients previously diagnosed with OSA;
and 1 patient with missing case status.
Statistical considerations
Descriptive statistics were performed on baseline charac-
teristics. Continuous variables were compared between
control and case groups using t-tests. Categorical vari-
ables were compared between control and case groups
using chi-square tests or Fisher’s exact test where appro-
priate. Covariates that significantly differed between the
COL and BE groups were evaluated further using a uni-
variate logistic regression model to identify predictors of
scoring at high risk for OSA on the Berlin Question-
naire. A multivariate logistic regression model was de-
veloped including covariates that were significant
predictors in univariate models by the likelihood ratio
test. Data were analyzed using SAS (9.2 for Windows,
SAS Institute Inc., Cary, North Carolina, USA).
Sensitivity Analysis
To account for possible misclassification of Barrett’s
esophagus patients as controls in the COL group, a sen-
sitivity analysis was performed assuming a 7% rate of
misclassification based on prior literature [6]. The odds
ratio describing the association between BE and being
BQ+ was calculated based on different assumptions re-
garding the BQ+ rate among these misclassified patients.
Results
Demographic characteristics, body mass indices, and
GERD symptoms of the three comparison groups are
presented in Table 1. Patients in the COL group were
somewhat younger than the BE group (mean age, 57 years
versus 63 years, p = 0.02). Although EGD patients had a
significantly lower mean self-reported BMI than the BE
group (27 kg/m2 versus 30 kg/m2), that in the COL group
was not significantly different from the BE group. Not sur-
prisingly, patients in the COL group were less likely to be
male and white. BE patients were significantly more likely
to report nocturnal regurgitation or nocturnal heartburn
symptoms than either of the control groups (Table 1). In
addition, BE patients reported more severe typical heart-
burn and regurgitation symptoms than either the EGD or
COL groups (Figure 1A and 1B).
Univariate logistic regression evaluating factors associ-
ated with BQ+ status revealed that BE was associated with
an increased risk for OSA compared with COL controlsbut not EGD controls (Table 2). Within the BE group,
56% of patients scored at high risk for OSA on the Berlin
Questionnaire (n = 30). In comparison, 42% of EGD pa-
tients (n = 26) were BQ+ (OR 1.73, 95% CI [0.83, 3.62]),
and 37% of COL patients (n = 64) were BQ+ (OR 2.08,
95% CI [1.12, 3.88]). On univariate logistic regression
among the BE and COL groups combined, age but not gen-
der or race was also associated with an increased risk for
OSA. Obese BMI based on self report, which does contrib-
ute to one symptom category of the Berlin Questionnaire,
was also associated with markedly increased risk for OSA.
A multivariate logistic regression model adjusting for age
(Table 3) revealed that the odds ratio for the association be-
tween BE and BQ+ status was no longer significant at 1.84
(95% CI 0.98, 3.47). Upon comparing the multivariate logis-
tic regression model containing age and BE status with the
nested model containing age alone, the multivariate model
did not provide significantly better fit by the likelihood ratio
test, although the p value was minimally greater than 0.05
(chi-square test = 3.55, corresponding to a p value of
0.0595). Therefore, after adjusting for age, the association
between BE and increased risk for OSA was no longer sta-
tistically significant. Likewise, a multivariate logistic regres-
sion model adjusting for age and BMI found no association
between BE and BQ+ status (Table 3).
Although the proportion of BQ+ patients was not signifi-
cantly different between the BE and EGD groups, BE pa-
tients were more likely to score positively for 2 of the 3
symptom categories on the Berlin Questionnaire: snoring
symptoms (56% for BE versus 32% for EGD, p = 0.01) and
the presence of obesity/HTN (74% for BE versus 48% for
EGD, p = 0.005). Figure 2 displays the proportion of sub-
jects scoring positively for each symptom category of the
Berlin Questionnaire among the 3 groups. However, within
self-reported BMI strata (normal, overweight, or obese),
there was no significant difference in snoring symptoms be-
tween the BE and EGD groups, suggesting that differences
in BMI could explain the initial differences in snoring
symptoms between the 2 groups. When BE patients were
compared with the COL group, the proportion of subjects
scoring positively for snoring symptoms or daytime somno-
lence did not differ significantly (56% for BE versus 45% for
COL, p = 0.18 for snoring symptoms; 29% for BE versus
20% for COL, p = 0.13 for daytime somnolence/drowsiness
while driving). BE patients were more likely to score posi-
tively for the 3rd BQ symptom category, presence of obes-
ity/HTN, although this did not reach statistical significance
(74% for BE versus 59% for COL, p = 0.05).
Because COL patients who were not getting upper en-
doscopy served as controls and could potentially have been
misclassified, we performed a sensitivity analysis to evalu-
ate the extent to which misclassification could have af-
fected our results. A previous study of 961 colonoscopy
patients undergoing upper endoscopy revealed that 6.8%
Table 1 Demographic characteristics, mean body mass index, and GERD symptoms among 3 comparison groups
BE (n = 54) EGD (n = 62) P value (BE vs. EGD) COL (n = 171) P value (BE vs. COL)
Mean age, years (SD) 63 (11.1) 60 (11.7) NS 57 (13.6) 0.001*
White (%) 53 (98.2) 59 (95.2) NS 70 (41.9)† <0.0001¥
Male (%) 38 (70.4) 36 (58.1) NS 75 (43.9) 0.001°
Mean BMI, kg/m2 (SD) 30 (5.9) 27 (5.5) 0.03* 28 (5.6) 0.06*
Heartburn symptoms (%) 43 (79.6) 33 (53.2) 0.003° 53 (31.0) < 0.0001°
Nocturnal heartburn symptoms (%) 27 (50.0) 16 (25.8) 0.01° 21 (12.3) <0.0001°
Regurgitation symptoms (%) 42 (77.7) 38 (61.3) 0.06° 41 (24.0) <0.0001°
Nocturnal regurgitation symptoms (%) 31 (57.4) 18 (29.0) 0.002° 18 (10.5) <0.0001°
SD, Standard deviation
NS, Not significant
BMI, Body mass index
* Independent samples t test with equal variances
° Chi-square test
†Among respondents; 4 subjects did not respond to the question about race.
¥ Fisher’s exact test
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history of heartburn symptoms, 8.3% had Barrett’s esopha-
gus, compared with 5.6% among those with no history of
heartburn symptoms [6]. We therefore assumed that 7%,
or 12, patients in the COL group in the current study
could have been misclassified and actually had Barrett’s
esophagus. Assuming that the BQ+ rate among these mis-
classified patients was 1) the same as that in the original
COL group (a conservative estimate) versus 2) the BQ+
rate in the original BE group, then the odds ratio would be
1.75 (95% CI 0.98, 3.13) for the former scenario, versus
2.28 (95% CI 1.27, 4.10) for the latter scenario. In all likeli-
hood, the true odds ratio probably lies somewhere in
between.
We explored the relationship between nocturnal GERD
and BQ+ status among all patients in the study, including
cases and controls. Among all patients with nocturnal
heartburn, the rate of BQ+ was 58% (n = 37), compared
with 37% (n = 83) among patients without nocturnal
heartburn (p = 0.003). Among all patients with nocturnal
regurgitation, 63% were BQ+ (n = 42), compared with 35%
(n = 78) among patients without nocturnal regurgitation
(p < 0.0001). We also examined the association between
nocturnal GERD symptoms (defined as either nocturnal
heartburn or regurgitation, or both) and scoring at high
risk for OSA within each study group (Table 4). Within
the BE and COL groups, BQ+ subjects were more likely to
report nocturnal GERD, although only 23% of BQ+ sub-
jects reported nocturnal GERD in the COL group. There
was no association between nocturnal GERD and BQ+ sta-
tus within the EGD group.
Discussion
The majority of BE patients in our pilot study scored at
high risk for OSA on the Berlin Questionnaire. After
adjusting for age and BMI, the association betweenBarrett’s esophagus and scoring at high risk for OSA com-
pared with the COL group was no longer statistically sig-
nificant. Because older age and higher BMI are risk factors
for OSA [30], these factors likely had a large effect on the
study results because the BE group was older than the
COL group and had a higher BMI than the EGD group.
Patients with known OSA were excluded from our study;
however, almost all of these patients came from the BE
group which could have affected our results. In our study,
37% of COL patients scored at high risk for OSA, which is
slightly greater than the 32%-36% rate previously described
in primary care settings and a cardiology referral clinic
[26,29]. Patients presenting for outpatient endoscopy at
our hospital may be a higher risk population than patients
in primary care settings, who in turn likely have a greater
prevalence of OSA than the general population [31]. None-
theless, the high rate of BQ+ status among BE patients in
our study is striking. Barrett’s esophagus patients may be
more likely to have obstructive sleep apnea than GERD pa-
tients without BE due to insulin/insulin growth factor
pathways which may have a role in the development of BE
[32]; obstructive sleep apnea is associated with insulin re-
sistance [20]. Since our study was conducted, two other re-
cent studies presented in abstract form have suggested that
BE is associated with obstructive sleep apnea [33] or ob-
structive sleep apnea characteristics [34]. Taken together,
these findings hold particular relevance because BE pa-
tients who undergo endoscopic surveillance or lengthier
endoscopic ablative procedures may thereby be at in-
creased risk for sedation-related complications. Benzodiaz-
epines and opioids can depress respiratory drive, decrease
upper airway reflexes, and decrease pharyngeal muscle
tone [35,36]. Propofol can also lead to upper airway col-
lapse [35,37]. These effects are particularly important for
patients with obstructive sleep apnea due to redundant
pharyngeal tissue and generally narrower airways [38].
Table 2 Univariate analysis of factors associated with BQ+
status
Odds ratio 95% Confidence interval
BE vs. EGD group 1.73 0.83, 3.62
BE vs. COL group 2.08 1.12, 3.88
Among BE and COL groups:
Age 1.03 1.004, 1.047
Male gender 1.32 0.78, 2.25
White race (vs. non-white) 1.11 0.65, 1.90
BMI
Normal 1.0
Overweight 2.37 1.03, 5.46
Obese 16.8 7.30, 38.76
Table 3 Multivariate analysis of factors associated with
BQ+ status among BE and COL groups
Odds ratio 95% Confidence
interval
Model containing age and BE status 1.73 0.83, 3.62
Age 1.02 1.00, 1.04
BE 1.84 0.98, 3.47
Model containing age, BE status,
and BMI
Age 1.03 1.00, 1.05
BE 1.51 0.72, 3.15
BMI
Normal 1.0
Overweight 2.32 0.99, 5.43
Obese 16.77 7.1, 39.42
Figure 1 Distribution of Severe Gastroesophageal Reflux
Symptoms by Group. Distribution of severe heartburn symptoms
(1A) and severe regurgitation symptoms (1B) by group. Severe
symptoms were defined as lifestyle-affecting. P values presented are
results of Mantel-Haenszel chi-square tests.
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risk for OSA. This high rate is not surprising since many
of these patients were likely undergoing EGD for GERD
symptoms, and previous studies suggest that GERD is as-
sociated with sleep complaints [15,16]. In addition,
Siupsinskiene and colleagues reported in abstract form re-
sults from a prospective Lithuanian study in which 42
OSA patients underwent upper endoscopy regardless of
whether they had upper GI symptoms. This study revealed
that 83.3% had pathologic GI findings: 64.3% had hiatal
hernia, 45.2% had erosive esophagitis, and 21.4% had
histological esophagitis [39]. There was no significant cor-
relation between OSA severity and frequency of endo-
scopic findings. Although there was no mention of
Barrett’s esophagus as an endoscopic finding, BE presum-
ably could have been masked by erosive esophagitis.In our study, BE patients were more likely than either of
the control groups to report nocturnal heartburn or noc-
turnal regurgitation. BE patients also reported more severe
typical GERD symptoms than patients in either control
group. These findings are consistent with previous studies
demonstrating higher esophageal acid exposure in BE pa-
tients [40,41]. Within the BE and COL groups, nocturnal
GERD was associated with BQ+ status, although the rate
of nocturnal GERD was low (23%) among BQ+ subjects in
the COL group. These findings raise questions of whether
BE could be associated with obstructive sleep apnea
through a higher incidence of nocturnal GERD or whether
nocturnal GERD itself increases the risk of obstructive
sleep apnea. Previous studies have been inconsistent in
demonstrating a link between nocturnal GERD and BE
[21-24,42]. The relationship between GERD and OSA is in-
completely understood. Nocturnal GERD was associated
with sleep complaints [16] or OSA symptoms [43] in large
cohort studies, and continuous positive airway pressure
improved GERD symptoms in OSA patients [17,18].
Figure 2 Distribution of Positive Responses for each Berlin
Questionnaire Symptom Category by Group. Distribution of
positive responses for each Berlin Questionnaire symptom category
by group. Category 1 was positive if the subject had persistent
snoring symptoms. Category 2 was positive if the subject had
persistent daytime somnolence and/or drowsiness while driving.
Category 3 was positive if the subject had a body mass index ≥ 30
kg/m2 or history of hypertension. BE, Barrett’s esophagus. EGD,
esophagogastroduodenoscopy control group. COL, colonoscopy
control group. Cat., category. * P ≤ 0.01 vs. EGD group.
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the number of nocturnal gastroesophageal reflux events as
measured by pH monitoring and impedance among OSA
patients without GERD, OSA patients with GERD, GERD
patients without OSA, and healthy controls [44]. In
addition, high-resolution manometry measurements in that
study suggested that during OSA events, gastroesophageal
junction and upper esophageal sphincter pressures actually
increased—changes which would be expected to prevent
rather than induce reflux events.
Our pilot study had several limitations. Our study was
limited by the use of open-access colonoscopy patients
who were not getting EGD as controls, since we assumed
that those patients did not have Barrett’s esophagus. The
decision to include the COL control group in our studyTable 4 BQ+ status within each study group by nocturnal GER
BE group (n = 54) EGD group (
nGER+ (n = 34) nGER- (n = 20) nGER+ (n = 2
BQ+ (%) 23* (67.6) 7 (35.0) 10 (47.6)
nGER, nocturnal gastroesophageal reflux symptoms (heartburn or regurgitation)
* p = 0.02 by chi-square test comparing nocturnal GERD symptoms within study grwas partially due to slow accrual of EGD controls. Based
on our sensitivity analysis, misclassification could have po-
tentially strengthened or weakened an association between
BE and BQ+ status. In addition, the study was limited due
to exclusion of patients with known OSA; since most of
these patients had Barrett’s esophagus, this could have
affected the study results. Our study was also limited
because results of the Berlin Questionnaire were not
confirmed with polysomnography. Previous validation of
the Berlin Questionnaire in a surgical patient population
demonstrated a sensitivity of 68.9%-87.2% at various
apnea-hypopnea index cutoffs [28]. Our assessment of
nocturnal GERD was based on patient self-assessment of
symptoms rather than an objective measure such as
esophageal pH monitoring. The Berlin Questionnaire is
partially based on self-reported BMI, which can vary sig-
nificantly and unpredictably from the true BMI value and
can potentially be misleading in very muscular patients.
Finally, a type II error might explain why the association
between BE and BQ+ status disappeared after adjusting
for age.
Conclusions
In summary, the findings from this pilot study demon-
strate that a high proportion of Barrett’s esophagus pa-
tients score at high risk for obstructive sleep apnea. This
finding is particularly important because many BE patients
undergo endoscopic surveillance, and a minority undergo
lengthier endoscopic procedures for ablation of dysplasia.
BE patients may therefore be periodically exposed to sed-
ation with its inherent risks. Given the high proportion of
BE subjects at high risk for OSA in our study, screening
for OSA should be considered in BE patients. At the very
least, raising awareness that BE patients are likely to score
at high risk for OSA may facilitate the judicious use of opi-
oids and sedatives, consideration for use of capnography
during sedation for lengthier endoscopic ablative proce-
dures, and more vigilant post-procedure monitoring in BE
patients undergoing surveillance endoscopy. Our results
also demonstrated that patients scoring at high risk for ob-
structive sleep apnea were more likely to report nocturnal
heartburn or acid regurgitation symptoms. Our findings
support a growing body of literature linking nocturnal
GERD to sleep disturbances. Future studies could explore
mechanistic links among Barrett’s esophagus, nocturnal
GERD, and obstructive sleep apnea.D symptoms
n = 62) COL group (n = 171)
1) nGER-(n = 41) nGER+ (n = 26) nGER- (n = 145)
16 (39.0) 15* (57.7) 49 (33.8)
oup
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